| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (NCT05361174) | Iovance Biotherapeutics, Inc. | 2022-07-20 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT04941365) | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-07-07 |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma (NCT04903119) | Rina Plattner | 2022-06-01 |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) (NCT05155254) | IO Biotech | 2022-05-17 |
| Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia (NCT07422779) | Institute of Oncology Ljubljana | 2022-03-01 |
| NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts (NCT04960059) | The Christie NHS Foundation Trust | 2022-02-11 |
| Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (NCT04955743) | Yale University | 2022-02-09 |
| PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (NCT05034536) | Massachusetts General Hospital | 2022-02-07 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (NCT04930783) | Dana-Farber Cancer Institute | 2022-01-03 |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases (NCT05026983) | M.D. Anderson Cancer Center | 2021-12-27 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (NCT04697576) | Carlo Contreras | 2021-10-20 |
| Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib (NCT05848219) | Novartis Pharmaceuticals | 2021-10-16 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299) | M.D. Anderson Cancer Center | 2021-09-23 |
| Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma (NCT04967196) | Mayo Clinic | 2021-09-16 |
| Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations (NCT05103891) | Pierre Fabre Medicament | 2021-09-03 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets (NCT04899921) | Dana-Farber Cancer Institute | 2021-06-30 |
| Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients (NCT06369428) | Novartis | 2021-06-23 |
| CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (NCT04060407) | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2021-06-15 |
| Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers (NCT07407166) | Institute of Oncology Ljubljana | 2021-05-01 |
| Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (NCT03743298) | Aivita Biomedical, Inc. | 2021-04-21 |
| Sargramostim (GM-CSF) + PD-1 (NCT04703426) | Dana-Farber Cancer Institute | 2021-04-16 |
| Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases (NCT03698162) | University of Southern California | 2021-04-13 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (NCT04698187) | Regeneron Pharmaceuticals | 2021-03-11 |
| Surgery of Melanoma Metastases After Systemic Therapy (NCT04242329) | Vastra Gotaland Region | 2021-03-11 |
| Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases (NCT04793737) | Karolinska University Hospital | 2021-03-08 |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation (NCT04633902) | California Pacific Medical Center Research Institute | 2021-03-03 |
| Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases (NCT04698161) | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 2021-02-25 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (NCT04695977) | Regeneron Pharmaceuticals | 2021-02-24 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (NCT04911998) | Pierre Fabre Medicament | 2021-02-02 |
| Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma (NCT04759846) | Pierre Fabre Medicament | 2021-01-21 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases (NCT04511013) | SWOG Cancer Research Network | 2021-01-06 |
| A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma (NCT04625205) | BioNTech US Inc. | 2020-12-01 |
| Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors (NCT03991741) | Gregory Daniels | 2020-10-07 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy (NCT04272658) | University Hospital, Brest | 2020-06-26 |
| Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden (NCT05611229) | Novartis Pharmaceuticals | 2020-06-16 |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (NCT04109456) | InxMed (Shanghai) Co., Ltd. | 2020-03-16 |
| TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (NCT04217473) | TILT Biotherapeutics Ltd. | 2020-02-26 |
| MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma (NCT03773744) | Turnstone Biologics, Corp. | 2020-02-15 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| SBRT as a Vaccination for Metastatic Melanoma (NCT04042506) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-11-26 |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332) | National Cancer Institute (NCI) | 2019-11-08 |
| Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (NCT04021420) | Assistance Publique - Hôpitaux de Paris | 2019-10-24 |
| Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma (NCT03225365) | Hospices Civils de Lyon | 2019-10-10 |
| A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab (NCT04955262) | Nektar Therapeutics | 2019-08-01 |
| Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (NCT03898908) | Grupo Español Multidisciplinar de Melanoma | 2019-07-18 |
| A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma (NCT03875079) | Hoffmann-La Roche | 2019-06-24 |
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma (NCT04337931) | Apexigen America, Inc. | 2019-06-12 |
| Radiation and Combination Immunotherapy for Melanoma (NCT03850691) | Masonic Cancer Center, University of Minnesota | 2019-05-28 |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade (NCT03474497) | Megan Daly, MD | 2019-05-20 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (NCT03645928) | Iovance Biotherapeutics, Inc. | 2019-05-07 |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation (NCT03925350) | California Pacific Medical Center Research Institute | 2019-03-20 |
| Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain (NCT03873818) | M.D. Anderson Cancer Center | 2019-02-21 |
| Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (NCT03817125) | Parker Institute for Cancer Immunotherapy | 2019-01-28 |
| Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (NCT03724968) | Elizabeth Davis | 2019-01-17 |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) (NCT03679767) | Incyte Corporation | 2019-01-09 |
| Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis (NCT05510466) | University Hospital, Montpellier | 2019-01-01 |
| A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases (NCT03625141) | Hoffmann-La Roche | 2018-12-13 |
| Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (NCT03646617) | Abramson Cancer Center at Penn Medicine | 2018-11-27 |
| Safety of ADU-1604 in Adults With Metastatic Melanoma (NCT03674502) | Aduro Biotech, Inc. | 2018-11-08 |
| A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors (NCT03708328) | Hoffmann-La Roche | 2018-10-15 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma (NCT03597282) | BioNTech US Inc. | 2018-10-08 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054) | Rahul Aggarwal | 2018-08-20 |
| STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain (NCT01904123) | M.D. Anderson Cancer Center | 2018-07-13 |
| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (NCT03425461) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (NCT03445533) | Idera Pharmaceuticals, Inc. | 2018-05-30 |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease (NCT03025256) | M.D. Anderson Cancer Center | 2018-05-02 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma (NCT03728465) | University Hospital Tuebingen | 2018-04-10 |
| A Study of ADXS-NEO Expressing Personalized Tumor Antigens (NCT03265080) | Advaxis, Inc. | 2018-03-28 |
| SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients (NCT03126461) | University of Texas Southwestern Medical Center | 2018-03-01 |
| Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma (NCT03047928) | Inge Marie Svane | 2018-02-22 |
| TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) (NCT03475134) | Centre Hospitalier Universitaire Vaudois | 2018-02-21 |
| A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes (NCT03526185) | Yale University | 2018-02-06 |
| Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma (NCT03297463) | Masonic Cancer Center, University of Minnesota | 2018-01-31 |
| A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126) | Asana BioSciences | 2018-01-19 |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors (NCT03864042) | Pfizer | 2018-01-02 |
| Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma (NCT03276832) | Mayo Clinic | 2017-12-20 |
| Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma (NCT03149029) | Massachusetts General Hospital | 2017-11-27 |
| Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors (NCT03326973) | Memorial Sloan Kettering Cancer Center | 2017-10-25 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss (NCT03131908) | M.D. Anderson Cancer Center | 2017-07-17 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab (NCT03123783) | Apexigen America, Inc. | 2017-07-10 |
| Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases (NCT03175432) | M.D. Anderson Cancer Center | 2017-06-15 |
| Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old (NCT03155217) | University Hospital, Montpellier | 2017-05-05 |
| Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02748564) | Rutgers, The State University of New Jersey | 2017-03-21 |
| Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers (NCT03073473) | Cota Inc. | 2017-02-28 |
| Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma (NCT02816021) | M.D. Anderson Cancer Center | 2017-02-14 |
| Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT03021460) | Mayo Clinic | 2017-01-31 |
| Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker (NCT02740920) | Canadian Cancer Trials Group | 2017-01-10 |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma (NCT02581930) | National Cancer Institute (NCI) | 2016-12-16 |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (NCT02910700) | M.D. Anderson Cancer Center | 2016-12-09 |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases (NCT02858869) | Emory University | 2016-10-04 |